Search Results - "Gebhardt, Kathleen"

Expression and activity of IL-17 receptor subunits in human cutaneous cells as targets for anti-IL-17 therapeutic antibodies by Wohlrab, Johannes, Gerloff, Dennis, Gebhardt, Kathleen

“…The key players in different chronic inflammatory skin diseases are cytokines belonging to the IL-17 group, IL-17 receptors and a T helper cell population,…”
Get full text

Resistance to BRAF Inhibitors: EZH2 and Its Downstream Targets as Potential Therapeutic Options in Melanoma by Uebel, Anne, Kewitz-Hempel, Stefanie, Willscher, Edith, Gebhardt, Kathleen, Sunderkötter, Cord, Gerloff, Dennis

“…Activating BRAF mutations occurs in 50-60% of malignant melanomas. Although initially treatable, the development of resistance to BRAF-targeted therapies…”
Get full text

Systemic Activation of Neutrophils by Immune Complexes Is Critical to IgA Vasculitis by Mayer-Hain, Sarah, Gebhardt, Kathleen, Neufeld, Matthias, Ehrchen, Jan M., Molyneux, Karen, Barratt, Jonathan, Nattkemper, Eva, Gerloff, Dennis, Roth, Johannes, Vogl, Thomas, Pappelbaum, Karin I., Sunderkötter, Cord

“…Abstract In IgA vasculitis (IgAV) perivascular deposition of IgA1 immune complexes (IgA-ICs) is traditionally considered the fundamental trigger for…”
Get full text

BRAF/EZH2 Signaling Represses miR-129-5p Inhibition of SOX4 Thereby Modulating BRAFi Resistance in Melanoma by Gebhardt, Kathleen, Edemir, Bayram, Groß, Elisabeth, Nemetschke, Linda, Kewitz-Hempel, Stefanie, Moritz, Rose K. C., Sunderkötter, Cord, Gerloff, Dennis

“…Many melanomas are associated with activating BRAF mutation. Targeted therapies by inhibitors of BRAF and MEK (BRAFi, MEKi) show marked antitumor response, but…”
Get full text